Drug Profile
Clobazam oral soluble film - Aquestive Therapeutics
Alternative Names: AQST-120; Clobazam - Aquestive Therapeutics; Clobazam OSF; SympazanLatest Information Update: 12 Jan 2023
Price :
$50
*
At a glance
- Originator MonoSol Rx
- Developer Aquestive Therapeutics
- Class Antiepileptic drugs; Anxiolytics; Benzodiazepines
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Lennox-Gastaut syndrome
Most Recent Events
- 09 Jan 2023 Aquestive Therapeutics has patent protection for Clobazam oral soluble film in USA
- 28 Oct 2022 Aquestive Therapeutics entered into Licensing and supply agreement with Assertio Holdings (subsidiary of Otter Pharmaceuticals) for Sympazan® (clobazam) oral film
- 27 Oct 2022 Assertio Therapeutics has patents pending for in Clobazam oral soluble film